Trial Profile
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 07 Jan 2017 Status changed from recruiting to completed.
- 15 Jul 2016 New trial record